{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:03:03Z","timestamp":1779814983261,"version":"3.53.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009259","name":"The University of Texas Medical Branch at Galveston Institute for Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001439"],"award-info":[{"award-number":["UL1 TR001439"]}],"id":[{"id":"10.13039\/100009259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.amjcard.2026.03.020","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:38:52Z","timestamp":1773905932000},"page":"19-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study"],"prefix":"10.1016","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9215-880X","authenticated-orcid":false,"given":"Ibrahim","family":"Mortada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0979-4904","authenticated-orcid":false,"given":"Aaron W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3430-1672","authenticated-orcid":false,"given":"Valerie","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-8839","authenticated-orcid":false,"given":"Shareef","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-3096","authenticated-orcid":false,"given":"Khaled","family":"Chatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7258-6887","authenticated-orcid":false,"given":"Mostafa","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0659-2100","authenticated-orcid":false,"given":"Thomas A.","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8754-358X","authenticated-orcid":false,"given":"Hani","family":"Jneid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2026.03.020_bib0001","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0002","first-page":"200198","article-title":"Residual cardiovascular risk, use of standard care treatments, and achievement of treatment goals in patients with cardiovascular disease","volume":"18","author":"Siniawski","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0003","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0004","doi-asserted-by":"crossref","first-page":"101740","DOI":"10.1016\/j.jacadv.2025.101740","article-title":"An observational study of cardiovascular outcomes of tirzepatide vs Glucagon-like peptide-1 receptor agonists","volume":"4","author":"Dani","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314631","article-title":"Tirzepatide: a systematic update","volume":"23","author":"Forzano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0006","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-024-02319-7","article-title":"Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.amjcard.2026.03.020_bib0007","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.eprac.2025.11.010","article-title":"Cardiovascular outcomes in adults with type 2 diabetes treated with tirzepatide: a systematic review and meta-analysis of real-world studies","volume":"32","author":"Kamrul-Hasan","year":"2025","journal-title":"Endocr Pract."},{"key":"10.1016\/j.amjcard.2026.03.020_bib0008","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0009","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/cvr\/cvad096","article-title":"Cardiorenal interactions in heart failure: insights from recent therapeutic advances","volume":"120","author":"Damman","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0010","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/jama.2025.14092","article-title":"Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction","volume":"334","author":"Kr\u00fcger","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0011","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-025-02710-8","article-title":"Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis","author":"Gonzales-Uribe","year":"2025","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0012","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.medj.2021.10.004","article-title":"Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors","volume":"2","author":"Cherney","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0019","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0013","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0014","doi-asserted-by":"crossref","first-page":"285","DOI":"10.14740\/jocmr6231","article-title":"Comparative efficacy of tirzepatide vs. Semaglutide in reducing body weight in humans: a systematic review and meta-analysis of clinical trials and real-world data","volume":"17","author":"Aamir","year":"2025","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0016","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0017","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","article-title":"Healthy user and related biases in observational studies of preventive interventions: a primer for physicians","volume":"26","author":"Shrank","year":"2011","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0018","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0021","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0022","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"Bmj"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0023","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0024","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0025","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/sim.4384","article-title":"Competing risks and the clinical community: irrelevance or ignorance?","volume":"31","author":"Koller","year":"2012","journal-title":"Stat Med"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0026","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0027","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/aje\/kwp107","article-title":"Competing risk regression models for epidemiologic data","volume":"170","author":"Lau","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0028","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/j.1475-6773.2005.00444.x","article-title":"Measuring diagnoses: ICD code accuracy","volume":"40","author":"O'Malley","year":"2005","journal-title":"Health Serv Res"},{"key":"10.1016\/j.amjcard.2026.03.020_bib0029","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CLEP.S288518","article-title":"Validation of ICD-10-CM diagnosis codes for identification of patients with acute hemorrhagic stroke in a national health insurance claims database","volume":"13","author":"Hsieh","year":"2021","journal-title":"Clin Epidemiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926001621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926001621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:07:56Z","timestamp":1779811676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926001621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S0002914926001621"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.03.020","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}